Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Qiu Wang, Lirong Ma, Yuanying Zhang, Lin Zhang, Yu An, Jia Liu, Guang Wang, Qiu Wang, Lirong Ma, Yuanying Zhang, Lin Zhang, Yu An, Jia Liu, Guang Wang

Abstract

Introduction: Irisin is a unique myokine with striking effects on regulating insulin sensitivity and energy metabolism. This study aimed to investigate the changes in serum irisin in patients with newly diagnosed type 2 diabetes mellitus (T2DM) following sitagliptin treatment.

Methods: Thirty-two patients with T2DM were treated with 100 mg/day sitagliptin for 16 weeks. Twenty age-, sex- and body mass index (BMI)-matched healthy subjects were enrolled as the control group. Irisin and metabolic parameters were measured at baseline and after treatment.

Results: Patients with T2DM had lower irisin levels than the controls (10.03 ± 2.06 vs. 13.06 ± 3.10 ng/ml, P < 0.01). Sitagliptin treatment significantly increased serum irisin levels in T2DM patients compared to baseline (11.18 ± 1.91 vs. 10.03 ± 2.06 ng/ml, P < 0.01). Increased irisin levels were associated with decreased fasting blood glucose (FBG) (β = - 0.24, P < 0.05) and glycosylated hemoglobin (HbA1c) (β = - 0.15, P < 0.05).

Conclusions: Sitagliptin treatment significantly increased serum irisin levels in patients with T2DM, and the increase of the irisin level was associated with decreases of FBG and HbA1c levels. These results suggest that irisin might be involved in the antidiabetic mechanisms of sitagliptin.

Trial registration: ClinicalTrials.gov identifier NCT04495881.

Keywords: Irisin; Sitagliptin; Type 2 diabetes mellitus.

Figures

Fig. 1
Fig. 1
Forest plots demonstrating associations between irisin and FBG (a), HbA1c (b), HOMA-IR (c), HOMA-β (d) and FINS (e) in mixed-effect linear models adjusted for potential confounders. FBG fasting blood glucose, HbA1c glycosylated hemoglobin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-β homeostasis model assessment of β-cell function, FINS fasting insulin, BMI body mass index, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride
Fig. 2
Fig. 2
Forest plots demonstrating associations between irisin and TC (a), HDL-C (b), LDL-C (c) and TG (d) in mixed-effect linear models adjusted for potential confounders. TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, BMI body mass index, FBG fasting blood glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin

References

    1. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–468. doi: 10.1038/nature10777.
    1. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324–337. doi: 10.1038/nrendo.2016.221.
    1. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98(4):E769–E778. doi: 10.1210/jc.2012-2749.
    1. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100(1):96–101. doi: 10.1016/j.diabres.2013.01.007.
    1. Yuksel MA, Oncul M, Tuten A, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract. 2014;104(1):171–175. doi: 10.1016/j.diabres.2013.12.025.
    1. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014;63(2):207–217. doi: 10.1016/j.metabol.2013.09.013.
    1. Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98(12):4899–4907. doi: 10.1210/jc.2013-2373.
    1. Chang CL, Huang SY, Soong YK, Cheng PJ, Wang CJ, Liang IT. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99(12):E2539–E2548. doi: 10.1210/jc.2014-1180.
    1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi: 10.1038/nrendo.2017.151.
    1. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes. 2010;3:31–41. doi: 10.2147/DMSO.S7327.
    1. Liu Y, Xu F, Jiang P. Effect of sitagliptin on expression of skeletal muscle peroxisome proliferator-activated receptor γ coactivator-1α and irisin in a rat model of type 2 diabetes mellitus. J Int Med Res. 2020;48(5):300060519885569.
    1. Classification I. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):S14–80.
    1. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24(2):362–365. doi: 10.2337/diacare.24.2.362.
    1. Bermúdez V, Cano R, Cano C, et al. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. Am J Ther. 2008;15(4):409–416. doi: 10.1097/MJT.0b013e318160b909.
    1. Xiang L, Xiang G, Yue L, Zhang J, Zhao L. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis. 2014;235(2):328–333. doi: 10.1016/j.atherosclerosis.2014.04.036.
    1. Zhang M, Chen P, Chen S, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014;18(11):1567–1572.
    1. Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27(4):365–369. doi: 10.1016/j.jdiacomp.2013.03.002.
    1. Huerta-Delgado AS, Roffe-Vazquez DN, Gonzalez-Gil AM, et al. Serum irisin levels, endothelial dysfunction, and inflammation in pediatric patients with type 2 diabetes mellitus and metabolic syndrome. J Diabetes Res. 2020;2020:1949415. doi: 10.1155/2020/1949415.
    1. Sanchis-Gomar F, Perez-Quilis C. The p38–PGC-1α–irisin–betatrophin axis: exploring new pathways in insulin resistance. Adipocyte. 2014;3(1):67–68. doi: 10.4161/adip.27370.
    1. Zhang Y, Li R, Meng Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes. 2014;63(2):514–525. doi: 10.2337/db13-1106.
    1. Huh JY, Mougios V, Kabasakalis A, et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab. 2014;99(11):E2154–E2161. doi: 10.1210/jc.2014-1437.
    1. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obes Metab. 2008;10(10):959–969. doi: 10.1111/j.1463-1326.2007.00839.x.
    1. Takihata M, Nakamura A, Tajima K, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013;15(5):455–462. doi: 10.1111/dom.12055.
    1. Shigematsu E, Yamakawa T, Kadonosono K, Terauchi Y. Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res. 2014;6(5):327–335.
    1. Herman WH, Dungan KM, Wolffenbuttel BHR, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A 1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(5):1689–1694. doi: 10.1210/jc.2008-1940.
    1. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne) 2019;10:80. doi: 10.3389/fendo.2019.00080.
    1. Kulkarni RN, Brüning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96(3):329–339. doi: 10.1016/S0092-8674(00)80546-2.
    1. Shirakawa J, Amo K, Ohminami H, et al. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011;286(29):25467–25476. doi: 10.1074/jbc.M110.217216.
    1. Duan H, Ma B, Ma X, et al. Anti-diabetic activity of recombinant irisin in STZ-induced insulin-deficient diabetic mice. Int J Biol Macromol. 2016;84:457–463. doi: 10.1016/j.ijbiomac.2015.12.049.
    1. Lee HJ, Lee JO, Kim N, et al. Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK. Mol Endocrinol. 2015;29(6):873–881. doi: 10.1210/me.2014-1353.
    1. de la Iglesia R, Lopez-Legarrea P, Crujeiras AB, et al. Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf) 2014;81(2):306–311. doi: 10.1111/cen.12383.
    1. Huh JY, Siopi A, Mougios V, Park KH, Mantzoros CS. Irisin in response to exercise in humans with and without metabolic syndrome. J Clin Endocrinol Metab. 2015;100(3):E453–E457. doi: 10.1210/jc.2014-2416.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever